Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SUPN stock price vs HGV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HGV's multiple
Needs HGV P/S.
Implied fair value · at SUPN's multiple
Needs SUPN P/S.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SUPN FY 2025 (ended Dec 31, 2025) · HGV FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Bear
$11.78
Base
$13.86
Bull
$15.94
Hilton Grand Vacations Inc. · implied price per share
Bear
$26.90
Base
$31.65
Bull
$36.40
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
3.53x
Net debt / EBITDA
Leverage against operating earnings
-6.69x
4.53x
Cash and equivalents
Liquid reserves on the balance sheet
$496.66M
$239.00M
Total debt
Interest-bearing obligations outstanding
$23.23M
$4.55B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SUPN can convert its 89.6% gross margin and 8.6% revenue growth into durable positive operating and net margins, then hold or selectively buy; otherwise, the current valuation looks hard to justify because the supplied P/S framework implies severe downside and the quality metrics remain weak.
On the supplied valuation basis, SUPN’s current price of $48.05 implies a P/S-derived value of just $10.44, or -78.3% downside. That gap is large even relative to HGV-implied range of $10.36 to $23.05, while SUPN still trades within its own historical band, suggesting the market is already assigning a rich multiple despite the cross-HGV comparison.
Supporting Metrics
